VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Aug 24, 2007 -- Inflazyme Pharmaceuticals Ltd. (Toronto:IZP.TO - News) today announced that they will not exercise their option to IPL455,903, a PDE4 inhibitor discovered and patented by the Company. Under the limited license granted to Helicon in January 2003, Inflazyme had 90 days to exercise its option after receiving certain information from Helicon which included the results of the first Phase 2a study.
